
By Sarina Isaacs, Reuters
Investing.com - Here are the hottest pieces of M&A news from the past week, as covered first on InvestingPro+.
Pan American Silver (NASDAQ:PAAS) Corp. and Agnico Eagle (NYSE:AEM) Limited announced a definitive binding $4.8 billion offer to acquire Yamana Gold (NYSE:AUY) Inc. to rival Gold Fields' (NYSE:GFI) planned acquisition of the Canada-listed miner. The deal would see pan American and Agnico Eagle split Yamana's mines between them. Gold Fields' all-stock author was worth $6.7 billion when first inked in May, but a slump in its shares has brought the offer's value to just north of $4 billion. Yamana rose 11.6% for the week; Pan American lost 6.5%; Agnico Eagle dropped 1.3%; and Gold Fields climbed 8%.
Johnson & Johnson (NYSE:JNJ) agreed to acquire Abiomed (NASDAQ:ABMD) for an upfront payment of $380 per share, or $16.6 billion. Abiomed shareholders will also receive a non-tradeable contingent value right (CVR) entitling the holder to receive up to $35 per share in cash if certain commercial and clinical milestones are achieved. Abiomed leapt 48.4% for the week; Johnson & Johnson slipped 1.4%.
Poseidon Acquisition agreed to buy marine and energy asset owner Atlas (NYSE:ATCO) Corp. for $15.50 per share, or $10.98 billion, in an all-cash transaction. Poseidon is an investment vehicle backed by Atlas's current chairman, David Sokol, among others. Atlas was up 3.3% for the week.
Voya Financial (NYSE:VOYA) agreed to buy Benefitfocus (NASDAQ:BNFT) for 10.50 per share, or $570 million, in an all-cash transaction. Benefitfocus soared 47.4% for the week; Voya was off 2.1%.
Marathon Oil (NYSE:MRO) said it would acquire Ensign Natural Resources' Eagle Ford assets for $3 billion in cash. Marathon Oil shares rose 5.2% for the week.
Begin trading today! Create an account by completing our form
At One Financial Markets we are committed to safeguarding your privacy.
Please see our Privacy Policy for details about what information is collected from you and why it is collected. We do not sell your information or use it other than as described in the Policy.
Please note that it is in our legitimate business interest to send you certain marketing emails from time to time. However, if you would prefer not to receive these you can opt-out by ticking the box below.
Alternatively, you can use the unsubscribe link at the bottom of the Demo account confirmation email or any subsequent emails we send.
By completing the form and downloading the platform you agree with the use of your personal information as detailed in the Policy.